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The term ‘‘interface dermatitis’’ (ID) involves a specific
histological inflammatory pattern that is characterized
by a cytotoxic lymphocytic infiltration and a hydropic
degeneration of the basal epidermal layer. ID is
typically seen in autoimmune skin disorders such
as lichen planus (LP), cutaneous lupus erythematosus
(CLE), and may also appear during immune reactions
against drugs, viruses, and tumors. Recent studies
have shown that the type-I IFN system is involved in
cutaneous autoimmune diseases characterized by ID.
IFNs induce the expression of proinflammatory
cytokines and chemokines, which support the cellular
immune response. The role of IFNs in ID is supported
by a close morphological association between the
expression pattern of IFN-inducible proteins and
the distribution of CXCR3þ lymphocytes. The IFN-
inducible chemokine CXCL10 is expressed in exactly
those areas where cytotoxic lymphocytes invade
the basal epidermis and cause keratinocyte death.
A similar picture can be found in early herpes
simplex viral skin lesions and viral warts, but also in
‘‘lichenoid’’ actinic keratosis and invasive squamous
cell carcinoma. These data suggest that ID morpho-
logically reflects a common IFN-driven cytotoxic
attack affecting the basal keratinocytes under
different conditions, which is important for antiviral
and antitumor immune response, but is inappropri-
ately activated in autoimmune skin disorders.
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THE TYPE-I IFN SYSTEM IS ACTIVATED IN SKIN DISEASES
WITH AN ID
‘‘Interface dermatitis’’ (ID) is a specific histomorphological
pattern of the basal epidermal layer, which is characterized
by vacuolar changes (liquefaction), appearance of apoptotic
keratinocytes (Civatte bodies), and infiltration of CD8þ
lymphocytes. Additionally, an upper dermal infiltrate of
varying intensity is typically seen (Patterson, 1991; LeBoit,
1993). Many skin diseases may manifest with an ID,
including autoimmune skin disorders (lichen planus (LP),
cutaneous lupus erythematosus (CLE), dermatomyositis,
lichen sclerosus), and immune reactions against drugs (drug
eruption, toxic epidermal necrolysis), viruses (erythema
multiforme, herpes simplex virus (HSV) infection, viral warts),
and tumors (‘‘lichenoid’’ actinic keratosis (LAK)) (Patterson,
1991; LeBoit, 1993). Lists of morphological ‘‘look-alikes’’
often provide insights into similar pathophysiologies of
disease processes. It had previously been suggested that an
antigen-specific, cell-mediated cytotoxic immune reaction
against basal keratinocytes might be the common feature
of ID (LeBoit, 1993).
During the last years it became evident that activation of
the type-I IFN system is involved in many skin-diseases
characterized by ID. Initially, Fah et al. reported in 1995 that
high amounts of the antiviral myxovirus A protein (MxA) can
be found not only in acute viral skin lesions (chickenpox,
herpes zoster, herpes simplex), but also in autoimmune
conditions like lupus erythematosus and LP. The MxA protein
is strongly induced by type-I IFNs (IFN-a/b), whereas
other cytokines (including IFN-g) are poor inducers. These
observations indicated an activation of the type-I IFN system
in these autoimmune skin disorders (Fah et al., 1995). Recent
molecular insights supported the view that the type-I IFN
system not only participates in antiviral and antitumor
immune defense, but also plays an important pathophysio-
logical role in autoimmune diseases that are characterized
by an ID-pattern, including LP, lupus erythematosus, and
dermatomyositis (Greenberg et al., 2005; Ronnblom et al.,
2006; Wenzel et al., 2007a, c).
TYPE-I IFN-ASSOCIATED INFLAMMATION IN LP
LP is regarded as the prototype autoimmune skin disorder
with ‘‘lichenoid’’ ID (Patterson, 1991; LeBoit, 1993). As
shown in Figure 1, the typical histological findings include a
basal hydropic degeneration of the epidermis, formation of
Civatte bodies, and a band-like lichenoid lymphocytic
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infiltrate in the upper dermis, which is dominated by T cells.
It has been suggested that autoreactive CD8þ T cells
recognizing epithelial antigens are involved in the patho-
genesis of LP (Sugerman et al., 2000; Santoro et al., 2004).
First evidence for a role of type-I IFNs in LP came from
clinical observations of an exacerbation of this disease after
therapeutical application of recombinant IFN-a (Herrera
Saval and Camacho Martinez, 1999; Pinto et al., 2003).
Large numbers of plasmacytoid dendritic cells (pDCs) are
detectable in LP skin lesions and may be an important source
of lesional type-I IFN production in LP (Figure 1; Santoro
et al., 2005; Wenzel et al., 2006a). Suomela et al. (2004)
found strong mRNA expression for the IFNa-inducible
proteins MxA and IFI27 in LP skin lesions, which agreed
largely with immunohistological studies revealing strong
MxA expression on the protein level (Fah et al., 1995;
Wenzel et al., 2006a). In situ hybridization analyses detected
IFN-a mRNA in the epidermis and within the inflammatory
infiltrate (Figure 1g; Wenzel et al., 2007a).
The interaction between the IFN-inducible chemo-
kines, CXCL9 and CXCL10, and their common receptor,
CXCR3, appears to play a central role in the development of
the typical ID pattern. Both chemokines are strongly
expressed in LP skin lesions, as demonstrated by several
in situ hybridization and PCR analyses (Spandau et al., 1998;
Tensen et al., 1999; Ichimura et al., 2006). In a recent
global gene-expression profiling analysis, we were able to
show that CXCL9 is the best marker to distinguish LP from
other inflammatory skin disorders such as atopic dermatitis
and psoriasis (Wenzel et al., 2007a). Importantly, several
IFN-regulated genes, including Mx1, IFI27, IFI30, G1P3,
IFN-regulatory factor-1 (IRF-1), IFITM1, and IFITM2, were
strongly induced in LP, supporting the involvement of the
IFN system in this disease (Figure 1h and i).
Immunohistological analyses confirmed strong expression
of the CXCR3 ligands in LP on the protein level. CXCL9
was found in the whole epidermis, whereas CXCL10 was
predominantly expressed in the hydropically degenerated
basal epidermal areas (Wenzel et al., 2006a, 2007a). Here,
cytotoxic CXCR3þ lymphocytes invade the epidermis and
induce keratinocytic apoptosis (Figure 1d and e). Interest-
ingly, CXCL10 is also found within the cytolytic granules
of infiltrating lymphocytes in LP. Its release along with the
cytotoxic proteins at the dermo-epidermal junction probably
represents an important self-recruiting mechanism for
CXCR3þ effector cells and might be involved in the chronic
interface inflammation typically seen in LP (Iijima et al.,
2003).
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Figure 1. ID in LP. LP is the prototype cell-rich ID. It presents histologically with the typical band-like ‘‘lichenoid’’ inflammatory infiltrate, vacuolization of
the basal layer, hyperkeratosis, hypergranulosis, and ‘‘sawtooth-like’’ acanthosis. Some Civatte bodies are found (a, H&E). CD3þ T cells dominate the
inflammatory infiltrate (b). CD8þ lymphocytes invade the basal epidermis (c). Large numbers of CXCR3 cytotoxic effector lymphocytes are found at the
dermo-epidermal junction and in the upper dermis (d, CXCR3: brown; granzyme B, red). Keratinocytes undergo apoptosis in exactly those areas where
lymphocytes infiltrate the epithelium (e, caspase 3). Large numbers of ‘‘natural IFN-producing’’ CD123þ pDCs are found within the band-like infiltrate (f).
In situ hybridization demonstrates strong IFN-a mRNA expression within the epidermis and the upper dermis (g). The role of type-I IFN production is supported
by detection of several IFN-regulated genes in gene-expression analyses of lesional LP-skin biopsies (h). The IFN-inducible chemokine CXCL9, which is
a ligand for CXCR3, was the best marker to distinguish LP from other inflammatory skin disorders such as atopic dermatitis (AD) and psoriasis (Pso). Bar¼100 mm
(a, b, c, f, g) or 500mm (d, e). Expression ratio (h, i) ranges from threefold downregulated (green) to threefold upregulated (red). Abbreviations: H&E,
hematoxylin–eosin; HC, healthy control.
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ROLE OF THE TYPE-I IFN SYSTEM IN ANTIVIRAL
IMMUNITY
From an evolutionary point of view, the type-I IFN system
most likely has a pivotal role in antiviral defense, including
coordination of the antiviral cellular immunity (Stetson and
Medzhitov, 2006). This became particularly clear when mice
lacking the IFN-a/b receptor died rapidly after dengue virus
infection (Shresta et al., 2004). How cells recognize the
presence of virus on the molecular and cellular level
remained unclear until recently. Now it has become evident
that viral nucleic acids are sensed by germline-encoded
pattern-recognition receptors (PRRs) (Akira et al., 2006). Two
complementary PRR systems account for most virus detection
(Stetson and Medzhitov, 2006). One class of PRRs, the
Toll-like-receptors (TLRs), are expressed on the cell surface
and in the endosomes of specialized immune cells such as
pDCs. TLR3 recognizes viral double-stranded DNA, TLR7
and 8 bind viral ssRNA, and TLR9 binds bacterial or viral
double-stranded DNA with CpG motifs (Kawai and Akira,
2006). Different adaptor molecules link the endosomal
viral recognition via TLRs with IFN-gene expression. TLRs7–9
use MyD88 for intracellular signal transduction. TLR3 uses
Toll/IL-1-receptor domain-containing adaptor inducing IFN-b
(TRIF) as an adaptor. Further downstream adaptor molecules,
including IRFs 3, 5, and 7, are needed to induce the
expression of type-I IFNs and other proinflammatory proteins
(Ronnblom et al., 2006).
The other class of PRRs, exemplified by the helicases
MDA5 and RIG-I, are expressed in the cytosol of most
cells. MDA5 binds viral dsRNA, RIG-I senses 3P-RNA, and
the recently identified DNA-receptor (DAI) recognizes viral
ssDNA (Akira et al., 2006; Stetson and Medzhitov, 2006;
Unterholzner and Bowie, 2008). These receptors induce
IFN expression via IFN-b-promoter stimulator 1 (IPS-1) (also
known as MAVS, VISA, or CARDIF). IPS-1 in turn triggers
signaling pathways, including activation of the protein
kinases TBK1 and IKKe, responsible for the phosphorylation
of IRF3, a key transcription factor involved in type-I IFN
synthesis (Vitour and Meurs, 2007).
Type-I IFNs induce several direct antiviral mechanisms.
IFN-induced proteins block viral replication, counteract cell
proliferation, and trigger apoptotic pathways in infected
human cells. Additionally, type-I IFNs bridge the innate and
adaptive immune system. They are able to activate DCs,
stimulate DC maturation, enhance cross-presentation and
T-cell-survival, and support subsequently the expression
of proinflammatory cytokines (Maher et al., 2007). IFN-
inducible chemokines play a central role in the recruitment of
effector immune cells into the skin (Stanford and Issekutz,
2003). Here, interactions between the chemokine receptor
CXCR3, which is expressed on pDCs, Th1-cells, and CD8þ
effector T-lymphocytes, and its IFN-inducible ligands,
the chemokines CXCL9 (MIG), CXCL10 (IP10), and CXCL11
(I-TAC) are important (Liu et al., 2005). A model of viral
IFN induction is given in Figure 2.
During viral infection of the epidermis, for example with
HSV or in verruca vulgaris (VV), cutaneous DCs become
activated by the initial innate immune response, migrate to
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Figure 2. Mechanisms of IFN induction in viral infection and autoimmune disease. Viral infections are sensed by two complementary systems of PRRs,
which recognize viral nucleic acids. One class of PRRs, the TLRs (TLRs 3, 7, 9), is expressed in the endosomes of specialized immune cells. The other class,
here exemplified by the helicases RIG-I and MDA5, is expressed in the cytosol of most cells. The PRRs use different adaptor molecules (Myd88, TRIF, IPS1) to
activate IRFs that induce expression of type-I IFNs. An autocrine loop via the IFN-ab receptor is important for the expression of IFN-inducible proteins (for a detailed
review, see Akira et al., 2006). Importantly, recent studies indicated that the IFN system is also involved in autoimmune disorders such as SLE. Here, immune
complexes comprising autoantibodies and endogenous RNA/DNA have been shown to trigger TLR7 or TLR9 (reviewed by Ronnblom et al., 2006).
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the regional lymph node, and mediate T-cell priming
(Yoneyama et al., 2005; Wuest et al., 2006). Intact TLR9-
and type-I IFN-signaling pathways are required to augment
HSV-1-induced chemokines CXCL9 and CXCL10 (Wuest
et al., 2006). The interaction between these CXCL chemo-
kines and their receptor, CXCR3, plays an important role in
the recruitment of anti-HSV-specific cytotoxic T-lymphocytes
(CTLs) into the target tissue (Lundberg and Cantin, 2003).
T-lymphocytes capable of IFN-g secretion and HSV-specific
cytolysis have been isolated from human herpetic lesions.
The subsequent resolution of HSV lesions is associated with
the detection of HSV-specific cytolytic CD8þ T-lymphocyte
activity, and requires IFN-g and either perforin- or Fas-
mediated cytolytic mechanisms (Dobbs et al., 2005). This
antiviral immune response represents a typical mechanism
of antigen-specific cytotoxic immunity leading to destruction
of virus-infected epidermal cells. Importantly, an ID pattern
with vacuolar degeneration along the basal layer and
Civatte bodies is often seen in early HSV skin lesions.
Older lesions show typical acantholytic, intra-epidermal
vesicles (Huff et al., 1981; Sumegi, 1982; Patterson, 1991).
A T-lymphocytic lichenoid inflammation with an ID pattern is
also regularly seen in VV (Kossard et al., 1980; Figure 3).
Typical immunohistological findings demonstrating the
expression pattern of an IFN-associated immune response in
VV, are depicted in Figure 4; MxA and CXCL9 are strongly
expressed within the whole epidermis, whereas CXCL10 is
found in exactly those areas where CXCR3þ CTL invade the
basal epidermal layer.
THE TYPE-I IFN SYSTEM IN LUPUS ERYTHEMATOSUS
Clinical observations suggested that type-I IFNs are also
involved in the pathogenesis of systemic lupus erythematosus
(SLE) for more than 20 years. Patients with acute SLE often
present with flu-like symptoms such as fever, fatigue, and
rash, which reflect high serum levels of type-I IFN, and
correlate with both disease activity and severity (Hooks et al.,
1981; Dall’era et al., 2005). Direct evidence for a role
of type-I IFNs in SLE came from clinical observations of
SLE exacerbation after treatment with recombinant IFN-a
(Ronnblom et al., 1991). These findings were supported
by results from several experimental mouse models. IFN
injection into NZB/W mice induced severe autoimmune
glomerulonephritis accompanied by increased titers of serum
anti-ssDNA and deceased survival (Adam et al., 1980).
Treatment of autoimmune lupus NZB x NZWF1 (B/WF1)
mice with IFN-releasing agents increased the titer of anti-
nuclear antibodies and the severity of glomerulonephritis
(Hasegawa and Hayashi, 2003). Moreover, introducing a null
mutation for the IFN-receptor gene into the autoimmune lpr
mice clearly reduces lupus-like disease (Braun et al., 2003;
Santiago-Raber et al., 2003). In humans, polymorphisms
of IFN-related genes were recently found to be associated
with an increased susceptibility for the development of
SLE (Graham et al., 2006).
Enhanced serum levels of IFN-a in SLE patients had
already been detected during the 1980s, but the source of IFN
remained unclear (Hooks et al., 1981). In 1999, Vallin et al.
(1999) observed that DNA-containing immune complexes
of SLE patients induced IFN-a production by pDCs. The
occurrence of these ‘‘interferonic’’ immune complexes is
associated with active disease (Vallin et al., 1999). During the
following years, Ronnblom et al. were able to show that these
immune complexes may contain endogenous nuclear anti-
gens bound to anti-dsDNA or snti-U1snRNP autoantibodies
(Lovgren et al., 2004). They act as potent ‘‘self-antigens’’ for
TLR7 and TLR9 (Barrat et al., 2005), and strongly induce type-
I production of human pDCs in vitro (Marshak-Rothstein,
2006; see Figure 2). The source of DNA and RNA fragments
in SLE patients is not yet identified, but recent studies showed
that apoptotic or necrotic cells can generate interferonic
DNA/RNA material (Lovgren et al., 2004). Since SLE patients
have a reduced clearance of dying cells, apoptotic RNA and
DNA fragments are available in SLE patients in vivo
(Herrmann et al., 2000; Gaipl et al., 2005).
During the last years it became evident, that the type-I IFN
system also participates directly in the pathogenesis of CLE
(reviewed by Wenzel and Tuting, 2007). The two major
disease subtypes, chronic discoid LE and subacute cutaneous
LE, typically show a histopathological ID pattern (Tebbe
et al., 1995). Patients with chronic discoid LE present with
characteristic scarring erythematous macules and plaques,
localized to the face or to the capillitium. Histologically a
T-cell-rich ID affecting the junctional zone of the epidermis
and the hair follicle is frequently observed. Cytotoxic
lymphocytes infiltrate the dermo-epidermal zone and induce
keratinocytic apoptosis (Figure 5; Wenzel et al., 2005b).
Patients with subacute cutaneous LE present with annular or
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Figure 3. ID in viral skin disorders. Antigen-specific T cells recognizing viral
antigens presented by infected keratinocytes are a hallmark of viral skin
infections by HSV or human papillomavirus. As shown in this figure, the
cytotoxic immune response may manifest with an ID pattern. Depicted are
the histological pictures of a VV biopsy. A dense lichenoid inflammatory
infiltrate that invades the basal epidermal layers is found in the upper dermis.
A hydropic degeneration with several Civatte bodies (arrows) is found in the
epithelium (a, hematoxylin–eosin). CD3þ T lymphocytes dominate the
inflammatory infiltrate (b). Numerous cells express cytotoxic markers such
as Tia1 (c). In those skin areas where the effector lymphocytes invade the
epithelium, keratinocytes undergo apoptosis (d, demonstrated by caspase 3
staining). Bar¼100 mm (a–c) or 500mm (d).
www.jidonline.org 2395
J Wenzel and T Tu¨ting
IFN-Associated Interface Dermatitis
GrBCXCL10CXCL9CXCR3MxA
VV
CD
LE
LP
D
M
G
vH
R
Li
AK
SC
C
H
C
Figure 4. The type-I IFN-associated cytotoxic inflammation in different types of ID. A comparative overview of the IFN-associated inflammatory immune
response found in different types of ID. A strong expression of type I IFN-inducible genes (MxA, CXCL9, CXCL10) is found in the epidermis and the upper
dermis, whereas lymphoid cells expressing the corresponding chemokine receptor CXCR3 dominate the inflammatory infiltrate. Granzyme B-positive cytotoxic
cells invade the epidermis and induce keratinocytic apoptosis in exactly those areas where the strongest CXCL10 expression is found. Some infiltrating
lymphocytes carry CXCL10þ granules (arrow). As described in detail in this review, a similar inflammatory picture is found in several immune reactions
that target epidermal viral, self-, or tumor antigens (LP, CLE, viral warts, non-melanoma skin cancer). However, it may also be found in other autoimmune
disorders (for example, dermatomyositis, lichen sclerosus) as well as in several reactive conditions (drug reactions, graft-versus-host disease) that are
accompanied by an ID pattern (Wenzel et al., 2006b, 2007b; J Wenzel et al., unpublished data). Bars¼ 100mm. Abbreviations: VV, verruca vulgaris;
CDLE, chronic discoid lupus erythematosus; LP, lichen planus; DM, dermatomyositis; GvHR, graft-versus-host reaction; LiAK, lichenoid actinic keratosis;
SCC, squamous cell carcinoma; HC, healthy control.
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gyrate macules and plaques in sun-exposed areas, including
shoulders, back, and arms. Lesional skin biopsies present
histologically with a more cell-poor epidermal ID
(Sontheimer, 2005). Antinuclear autoantibodies are found in
20–80% of CLE cases, depending on the underlying sub-
type (Wenzel et al., 2000; Crowson and Magro, 2001).
In particular, anti-SSA/Ro and anti-SSB/La antibodies are
frequently found in CLE patients and associate closely with
photosensitivity (Norris, 1993; Orteu et al., 2001).
First evidence for a role of the type-I IFN system in CLE
again came from clinical observations: Patients with wide-
spread CLE skin lesions often present with flu-like symptoms,
similar to SLE patients. These symptoms are associated with
enhanced serum levels of the type-I IFN-inducible protein
MxA, and upregulation of T-cell activation markers such
as HLA-DR in peripheral blood (Wenzel et al., 2005a, c).
Large numbers of ‘‘natural type-I IFN-producing’’ pDCs are
found in CLE-skin specimens (Blomberg et al., 2001; Farkas
et al., 2001), accompanied by strong induction of the
MxA protein and of the IFN-inducible chemokines CXCL9
and CXCL10, which mediate the recruitment CXCR3þ
effector cells (Meller et al., 2005; Wenzel et al., 2005c;
Wenzel and Tuting, 2007). Accordingly, the number of
peripheral CXCR3þ T cells is significantly diminished in CLE
patients with acute widespread skin lesions (Wenzel et al.,
2005c). The distribution of IFN-inducible proteins reflects
the histological pattern that is typically seen in different
CLE subtypes (Wenzel et al., 2007c). Importantly, CXCL10 is
expressed in exactly those epidermal areas where CTLs
invade the basal layer, suggesting a role of this chemokine in
the typical ID pattern (depicted in Figure 4). Some infiltrating
lymphocytes carry CXCL10-positive granules (Wenzel and
Tuting, 2007; Wenzel et al., 2007c).
The primary mechanisms of IFN induction in CLE are still
unclear, but TLR activation by immune complexes, similar to
SLE, might play a role. Apoptotic cells accumulate in the
skin of patients with CLE after UV irradiation, probably as a
result of impaired or delayed clearance (Kuhn et al., 2006).
This is supported by recent observations from autoimmune,
non-obese diabetic mice that demonstrated an increase
in apoptotic cell load following UV-light exposure to
keratinocytes when compared with control strains (O’Brien
et al., 2006). The non-engulfed cells may undergo secondary
necrosis and release proinflammatory compounds and
potential autoantigens, which may support the formation of
skin lesions in this disease (Kuhn et al., 2006). Additionally,
a DNA-damage response induced by UV light might be
involved.
Recently, we developed a hypothetical model for a vicious
proinflammatory circle in CLE: a primary, still unknown,
stimulus induces the lesional expression of type-I IFNs and of
proinflammatory, IFN-dependent cytokines, including CXCL9
and 10. Earlier observations suggest that UV light might play
a pivotal, initiating, role (Norris, 1993; Sontheimer, 1996).
Subsequently, the activated IFN-system drives the recruit-
ment of CXCR3þ effector lymphocytes and pDCs into the
skin. At least three different self-perpetuating mechanisms
could be envisioned, which may support the chronic
inflammation seen in CLE: (i) some infiltrating lymphocytes
carry CXCL10 in their granules, which is released together
with the cytotoxic proteins, and might support a direct
‘‘lymphocyte self-recruitment’’, (ii) recruitment of CXCR3þ
pDCs augments production of lesional type I IFNs, which
again perpetuates the lesional inflammation, and (iii) the
cytotoxic lesional inflammation leads to cell destruction and
impaired apoptosis, which again induces expression of
several proinflammatory mediators and the release of nuclear
fragments. This drives the lesional inflammation, especially
in the basal epidermal areas with CTL invasion, and may,
in part, be responsible for the ID pattern seen in CLE
(Wenzel and Tuting, 2007).
PRESENCE OF A HISTOLOGICAL ID PATTERN IN (PRE-)
MALIGNANT KERATINOCYTIC NEOPLASMS
A histological ID pattern is also frequently seen in (pre-)
malignant keratinocytic neoplasms of the skin such as actinic
keratosis (AK) and squamous cell carcinoma (SCC). AK is the
most frequently occurring form of ‘‘carcinoma in situ’’ that
is commonly seen in sun-damaged skin. Left untreated, this
condition has an approximate risk of up to 10% risk for
transition into invasive SCC. AK presents histologically with
atypical keratinocytes and a disordered epidermal structure,
as well as with solar elastosis in the dermis. UV-induced
mutations of the p53 tumor-suppressor gene are found in the
majority of AKs and appear to play a central pathogenetic
role in AKs and SCCs (Nomura et al., 1997). Inflammatory
changes, including a vacuolar degeneration of the basal cell
layer with some keratinocytes and a band like T-cellular
inflammatory infiltrate, are often seen in AKs. These lesions
are termed ‘‘lichenoid’’ AK, due to the histological simila-
rities with LP (Prieto et al., 1993; Hussein and Ahmed, 2005).
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Figure 5. ID in CLE. The typical histological findings in chronic discoid
CLE include a vacuolar degeneration of the basal epidermal layer with
Civatte bodies (arrows) and infiltration of lymphoid cells (a). Dermal changes
include a dense perivascular and peradnexal infiltration accompanied
by mucin depositions. The lymphoid cells are mostly CD3þ T cells (b),
which express cytotoxic markers such as Tia1 (c) and are accompanied
by keratinocytic apoptosis in basal epidermal layers (d).
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The lichenoid inflammation pattern is regarded to reflect
an immunological reaction against malignant transformed
keratinocytes (Tan and Marks, 1982). This assumption is
supported by the fact that AK has a great tendency for
spontaneous regression (Marks, 1986). The frequency of AK is
increased in immune-suppressed patients, demonstrating the
role of a functional immune system (Ulrich et al., 2003).
CD3þ T-lymphocytes, including numerous Tia1þ cytotoxic
T cells, dominate the mononuclear infiltrate in inflammatory
AK (Hussein and Ahmed, 2005). Similar findings were also
made in invasive SCCs. Here, an ID-like histological pattern
may be seen at the tumor invasion front, making it difficult to
distinguish initial SCC from CLE in some cases (Kurihara and
Hashimoto, 1985; Zedek et al., 2007). Cytotoxic T cells
infiltrating SCCs have been shown to specifically recognize
mutated epitopes of p53 involved in keratinocyte transforma-
tion, supporting a role of this immune response in tumor
control (Black and Ogg, 2003). As depicted in Figure 4, the
lichenoid inflammation in AK may be accompanied by a
similar immunohistochemical-pattern as seen in autoimmune
IDs. Strong expression of MxA and CXCL9 is found in the
epidermis and within the inflammatory infiltrate. Recruitment
of pDCs and CXCR3þ cytotoxic lymphoid cells, as well as
CXCL10 expression, is detectable in exactly those areas with
hydropic degeneration of the basal epidermis. Numerous
CD123þ pDCs are found at the dermo-epidermal junction,
and CXCR3þ cytotoxic effector cells infiltrate the epithelium
in areas where keratinocytes undergo apoptosis (Figure 6).
A similar expression pattern of IFN-inducible proteins is also
found in several SCC specimens (Figure 4). Gene-expression
analyses of SCCs show upregulation of numerous IFN-
associated genes (Mx1/MxA, IRF1, IFI30, CXCL9). This list
of IFN-associated genes in SCCs (depicted in Figure 6f) agrees
largely with the ‘‘IFN signature’’ originally described in SLE
patients (Baechler et al., 2003; Bennett et al., 2003; J Wenzel
et al., unpublished data). Interestingly, this IFN signature was
almost absent in organ-transplant recipients under immuno-
suppressive therapy, who have a significantly poorer clinical
prognosis (Figure 7).
TYPE-I IFNS AND TUMOR IMMUNOSURVEILLANCE
IN THE SKIN
Burnet (1970) already hypothesized in 1970 that the immune
system is able to detect and eliminate transformed cells.
This ‘‘immunosurveillance hypothesis’’ has been contro-
versially debated for many years (Dunn et al., 2004). Clinical
observations directly support a role for the immune system in
tumor growth control, since the incidence of skin cancer is
significantly enhanced in organ-transplant recipients under
long-term immunosuppression (Alam and Ratner, 2001;
Ulrich et al., 2003). Direct evidence that the type-I IFN
system participates in tumor immunosurveillance came from
experiments with genetically engineered mice that lacked
genes coding for IFN receptors or IFN-signaling molecules.
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Figure 6. Type I IFN associated junctional inflammation in non-melanoma skin cancer. LAK is regarded to reflect an immunological reaction against malignant
transformed keratinocytes. Here, a dense band-like ‘‘lichenoid’’ inflammatory infiltrate consisting of cytotoxic CXCR3þ lymphocytes is typically seen
(a, hematoxylin–eosin; b, CXCR3 (brown) and granzyme B (red) co-staining). Numerous CD123þ pDCs are found along the dermo-epidermal junction
(c). Keratinocytic apoptosis (demonstrated by caspase 3 staining) in areas where lymphocytes invade the epidermal layer (d). Note the disordered structure
and the nuclear atypia of the epidermis, which are typically seen in AK. An ID-like pattern (e, hematoxylin–eosin) and an IFN-associated inflammation (f)
may also be present in invasive SCC. Results of a gene-expression analysis in 40 SCC samples, followed by unclassified clustering (f). Here, two distinct
SCC subsets were identified, one with a strong expression of IFN-inducible genes (þ ) and one without () them. Interestingly, almost all SCC patients
who received long-term immunosuppression due to organ transplantation (red points) clustered into the IFN () group. (The expression ratio (f) ranges from
threefold downregulated (green) to threefold upregulated (red).) Bars¼ 100mm (a, b, c, e) or 500mm (d).
2398 Journal of Investigative Dermatology (2008), Volume 128
J Wenzel and T Tu¨ting
IFN-Associated Interface Dermatitis
These mice not only succumb to viral infections, but are
also more prone to develop carcinogen-induced epithelial
or mesenchymal tumors (Shankaran et al., 2001; Dunn et al.,
2005). DNA damage, which is associated with neoplastic
cellular transformation, has been suggested to play a signi-
ficant role in IFN induction in tumors (Xu, 2006). The DNA-
damage response activates innate immunity via stimulation of
IRF1 and IRF3, which both induce the expression of type-I
IFNs (Taniguchi et al., 2001; Barnes et al., 2002). Addition-
ally, DNA damage is associated with enhanced expression of
ligands, which are involved in the activation of natural killer-
and CD8þ T-cells during infection or neoplastic transforma-
tion (Gasser et al., 2005; Xu, 2006). The IFN-associated
inflammatory reaction, leading to the ID pattern in LAK and
SCC, appears to reflect a cellular tumor-antigen-specific
immune response targeting the basal epidermal areas in LAK
and the invasive tumor cells in some SCCs ( J Wenzel et al.,
unpublished data).
AN IFN-ASSOCIATED CYTOTOXIC CELLULAR IMMUNE
RESPONSE AGAINST VIRAL, SELF-, OR TUMOR
ANTIGENS IS A COMMON PATHOGENETIC FEATURE
IN ‘‘ID’’
The histological ‘‘ID’’ pattern is found in a large spectrum
of skin diseases, including autoimmune, infectious, reactive,
and neoplastic disorders. We propose that this pattern
morphologically reflects a cytotoxic cellular immune res-
ponse against keratinocytes, which is associated with
activation of the type-I IFN system. In viral skin infections,
CTLs recognize viral antigens presented by infected
keratinocytes via major histocompatibility-I (Mikloska et al.,
1996). Consequently, an ID pattern may be seen in early
HSV lesions, whereas older lesions show acantholytic,
intra-epidermal vesicles (Huff et al., 1981). In cutaneous
autoimmune diseases, keratinocytic autoantigens may play
a pivotal role: ‘‘autocytotoxic’’ CD8þ T cells recognizing
keratinocyte antigens have been identified in LP (Sugerman
et al., 2000). In cutaneous lupus erythematosus, immune
complexes comprising antinuclear antibodies and nuclear
antigens, which are released after UV-light exposure, may
stimulate IFN pathways and support lesional inflammation.
This stimulation probably depends on TLR-mediated recogni-
tion of endogenous nucleic acids in the endosome of
specialized immune cells, since chloroquine (which blocks
endosomal acidification) is an effective drug for this disease
(Rutz et al., 2004). Additionally, CTLs recognizing epidermal
autoantigens might play a role in some CLE subsets
(Wenzel and Tuting, 2007). Interestingly, an activated IFN
system appears also to be involved in the pathogenesis
psoriasis (Boyman et al., 2004; Lande et al., 2007). However,
this disease does not typically present with ID, and here
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Figure 7. The common pathogenetic mechanisms for a type-I IFN-associated cytotoxic inflammation in viral infection, autoimmune disease, and antitumor
immunity. This model depicts the common mechanisms involved in antiviral, autoimmune, and antitumor immune reactions. In the case of a viral infection
of keratinocytes, cutaneous DCs become activated by the initial innate immune response in the induction phase. DCs then migrate to the regional lymph
node and induce a virus-specific T cellular immune response. In autoimmune conditions, such as LP and CLE, infiltrating lymphocytes are supposed to
recognize keratinocytic autoantigens and nuclear fragments. In non-melanoma skin cancer, CTLs have been shown to recognize mutated epitopes of p53
involved in keratinocyte transformation. Independently from these etiopathogenetic differences, a similar ID-like pattern due to cytotoxic lymphocytes
that infiltrate the basal epidermal layers and induce keratinocytic apoptosis may be seen in all these diseases in the early effector phase. In older lesions,
during the late effector phase, the characteristic histopathological differences between these conditions are found. Viral lesions show the typical acantholytic,
intra-epidermal vesicles. CLE presents with a chronic ID. In non-melanoma skin cancers, the mechanism of tumor immunosurveillance and tumor
immunoediting evolve their impact (review by Dunn et al., 2006).
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appears to be less relevant than in CLE or LP (Wenzel et al.,
2008).
An ID-like pattern may also be found in LAK and in SCC.
Here, neoplastic transformed keratinocytes are probably the
main target of the immune cells and CTLs may specifically
recognize tumor-specific antigens such as mutated epitopes
of p53 (Black and Ogg, 2003).
Taken together, we show that skin disorders, which
are histologically characterized by an ID pattern, share
a common immunohistological picture, with epidermal
expression of the IFN-inducible proteins MxA, CXCL9, and
CXCL10 accompanied by infiltrating CXCR3þ cytotoxic
lymphoid cells. In all investigated ID conditions, independent
from the different pathogenetic background, CXCL10 is
expressed in exactly those areas where CXCR3þ CTLs
infiltrate the basal epidermis and induce keratinocytic apop-
tosis. Gene-expression analyses revealing a lesional ‘‘IFN
signature’’ support the role of type-I IFNs in these conditions.
These data indicate that the common molecular and
cellular basis underlying the morphological picture of ID is
an IFN-associated cytotoxic attack against the basal keratino-
cyte layers.
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